Form 4: Aclaris Therapeutics Interim CEO Exercises Stock Options and Sells Shares to Cover Costs

Aclaris Therapeutics' Interim CEO, Neal Walker, exercised stock options and sold shares to cover the exercise price and tax obligations.

Summary

• A Form 4 filing reveals that Neal Walker, Interim CEO of Aclaris Therapeutics, exercised 118,840 stock options at a price of $1.52 per share on December 4, 2024.
• Following the exercise, Mr. Walker sold 68,343 shares at $3.76 per share to cover the exercise price and tax obligations.
• After these transactions, Mr. Walker directly owns 1,433,630 shares of Aclaris Therapeutics common stock.
• The stock options were fully vested and exercisable on December 4, 2024, with an expiration date of December 7, 2024.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation, with no indication of positive or negative sentiment.

Industry Context

This is a routine filing related to executive compensation and is common practice for company insiders who hold stock options.

Comparison to Industry Standards

• Stock option exercises and subsequent sales to cover costs are standard practice for executives in publicly traded companies.
• The prices at which the options were exercised and shares were sold are within the typical range for such transactions.

Stakeholder Impact

• The transaction has a minor impact on the total number of shares outstanding.

Key Dates

Keywords

stock options, insider trading, executive compensation, ACRS, Aclaris Therapeutics, Form 4, Neal Walker